Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 8/20 | 0.68 |
| ▸ | SYK | P43405 | 7/20 | 0.42 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 3/20 | 0.38 |
| ▸ | IDH2 | P48735 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2138274 | 0.83 | HDAC4 (0.56) | HDAC4SYKSLC6A7IDH1IDH2 | |
| SCHEMBL12498834 | 0.81 | HDAC4 (1.00) | HDAC4 | |
| SCHEMBL12498836 | 0.81 | HDAC4 (1.00) | HDAC4 | |
| SCHEMBL15768990 | 0.81 | HDAC4 (0.74) | HDAC4SYKSLC6A7POLB | |
| SCHEMBL12499633 | 0.77 | HDAC4 (0.68) | HDAC4SYKSLC6A7 | |
| SCHEMBL15768991 | 0.77 | HDAC4 (0.68) | HDAC4SYKSLC6A7 | |
| SCHEMBL28213510 | 0.75 | KMT2A (0.53) | HDAC4IDH1IDH2LMNA | |
| SCHEMBL15606874 | 0.75 | HDAC4 (1.00) | HDAC4SYKSLC6A7 | |
| SCHEMBL15606850 | 0.75 | HDAC4 (1.00) | HDAC4SYKSLC6A7 | |
| SCHEMBL15606946 | 0.74 | HDAC4 (0.76) | HDAC4SYKSLC6A7IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | HDAC4 785/4885SYK 4466/4885SLC6A7 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.